Menu
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Innovative Therapies in Europe
Session 2: Is Zynteglo representative for the ATMPs failure in Europe? Are EU systems broken for innovative therapies?
Session Chair(s)
Alexander Natz, JD
- Secretary General
- European Confederation of Pharmaceutical Entrepreneurs, Belgium
Topics covered in this session include:
- Case study & domino effect
- The regulatory aspects
- Historical background for withdrawals
Speaker(s)
Sophie Schmitz
- Managing Partner
- P4A Partners for Access, Netherlands
The Zolgensma Experience – Can one-time ATMP’s be successfully commercialized in Europe?
Oswald Bentinck
- Vice President, Global Head of Value & Access
- Rocket Pharmaceuticals, Inc., United States